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Abstract
Background: The aim of this study was to determine the frequency of exposure to different sensitizing events (SEs) and to
assess their effects on human leucocyte antigen (HLA) alloimmunization in transplant candidates using two different HLA
antibody screening techniques: complement-dependent cytotoxicity (CDC) and Luminex.
Methods: This retrospective study included HLA antibody screening results for 163 patients on the kidney transplant wait-
ing list (WL) tested from March 2012 until the end of December 2015 at the Tissue Typing Laboratory, Rijeka, Croatia. All
sera samples were tested using the CDC and Luminex techniques in parallel.
Results: Two-thirds of the patients [114 (70%)] on the WL were exposed to transfusions, pregnancies and/or kidney trans-
plant. The pre-transplant sera of 104 (63.80%) patients were negative for antibodies. In the sera of 23 (14.11%) patients, HLA
antibodies were detected by CDC and Luminex and in the sera of 36 (22.09%) patients by Luminex only.
Conclusion: In patients on kidney WL, previous organ transplantation represents the strongest immunogenic stimulus,
followed by blood transfusions (the most frequent SE) and pregnancies. Although Luminex is more sensitive than CDC in
HLA antibody detection, the decision on unacceptable HLA antigens in WL patients has to be based on the results of both
assays and the patient’s immunization history.
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Introduction
Different sensitizing events (SEs), such as blood transfusions, preg-
nancies and previous transplants, may induce the development of
alloantibodies against human leukocyte antigen (HLA) [1, 2]. In the
organ recipient, preformed antibodies against graft antigens
[donor-specific antibodies (DSAs)] may cause acute (hyper-acute)
or chronic transplant rejection. The patients wait longer for trans-
plantation and extended dialysis treatment results in lower graft
survival than in non-sensitized patients [3–5]. Post-transplant
development of de novo donor-specific antibodies causes a higher
incidence of graft rejections and increased risk of graft loss [6].
The HLA system is the most polymorphic system in humans.
The complexity of antigenic epitopes represents a significant
challenge for tissue typing laboratories (TTLs) in developing
appropriate methods to detect and characterize the repertoire
of HLA antibodies present in sensitized transplant candidates.
The conventional and most widely used method for determin-
ing HLA antibodies is the cell-based complement-dependent cyto-
toxicity (CDC) assay that was introduced by Terasaki and
McClelland in the early 1960s [7]. The CDC technique has been in
use at TTL Rijeka since 1971, when the laboratory was founded
as the first one in Croatia. The technique is based on HLA mole-
cules displayed in their natural configuration [2]. In HLA anti-
body screening, the patient’s serum is incubated with a panel of
HLA-typed T and/or B lymphocytes, whose HLA alleles provide
a representative sample of the studied population. Results are
expressed as the percentage of panel lymphocytes that react
with a patient’s serum [panel reactive antibodies (PRA)]. As the
same technique is used for crossmatching between the recipi-
ent serum and the potential donor’s lymphocytes, PRA is useful
in assessing the probability of a negative crossmatch result [8].
However, the CDC assay has a number of shortcomings related
to the possibility of false negative (due to low antibody titres,
non-cytotoxic antibodies or antibodies to HLA class II) or a
false-positive result (the presence of autoantibodies, non-HLA
antibodies or immune complexes) [9].
One of the main consequences of the CDC method’s lack of
sensitivity is the considerable rate of graft failure in transplan-
tation after a negative CDC crossmatch [10]. In order to improve
graft survival, new antibody detection methods were intro-
duced, including flow cytometry (FC) and solid phase assay
(SPA)–enzyme-linked immunosorbent assay (ELISA) and
Luminex technology. While FC is cell based, SPA methods use
purified HLA molecules attached to plates (ELISA) or micro-
spheres (Luminex). These methods can detect lower levels of
HLA antibodies, allowing more precise determination of the
HLA antibody specificity and differentiation of antibodies that
activate complement from those that are non-complement fix-
ing [11]. Currently the Luminex technology is the most sensitive
and has been in use at TTL Rijeka since 2012 [12]. It is a semi-
quantitative bead-based immunoassay for detection of immu-
noglobulin G (IgG) and IgM antibodies to class I and class II HLA
molecules that combines FC (xMAP technology) and fluorescent
microparticles coated with HLA antigens at a high concentra-
tion [9]. This technique enables identification of very low titres
of class I and II HLA antibodies, accurate definition of acceptable
and unacceptable HLA antigens in highly sensitized patients,
and determination of epitope specificity, which is important for
graft outcome. It is very useful in DSA monitoring after trans-
plantation. This technology is also highly sensitive, leading to
the detection of clinically irrelevant antibodies. While some
specificities detected by SPA are considered to be relevant, they
are not an absolute contraindication to transplantation [1, 8].
The purpose of this study is to determine the frequency of
exposure to SEs such as organ transplantation, blood trans-
fusion and pregnancy and to assess their effects on HLA alloim-
munization in patients on the kidney transplant waiting list
(WL) using two different HLA antibody screening techniques in
parallel: CDC and Luminex.
Materials and methods
We performed retrospective analysis of the HLA antibody
screening results for 163 patients on the kidney transplant WL
in Rijeka. A total of 664 sera samples were tested from March
2012 until the end of December 2015. Sera from all patients were
tested by CDC, with or without di-thiotheitrol (DTT), and
Luminex techniques in parallel. In order to compare the two
techniques in terms of their detection of HLA IgG antibodies
only, nine patients were excluded from the study, as their sera
revealed the presence of non-HLA and/or IgM antibodies.
Patients with a positive result in at least one serum sample
were considered to be sensitized.
Information on SEs was obtained from potential recipients,
their nephrologists and transfusion protocols for patients who
underwent haemodialysis in Rijeka and from the questionnaire
that accompanied each sample.
In our centre, patients on the WL are screened for HLA anti-
body presence every 3 months, four times per year, using CDC
and Luminex techniques in parallel.
In the CDC assay the patient’s serum is incubated with a
panel of 50 HLA-typed unseparated T and B lymphocytes fol-
lowing standard procedures. HLA antibody screening was per-
formed with and without DTT addition. A PRA> 5% was
considered positive.
Serum screening by Luminex was performed in two stages
according to the manufacturer’s instructions. The first stage was
tested by LIFECODES LifeScreen Deluxe Beads, LMX (Immucor
Transplant Diagnostics, Stamford, CT, USA). Serum with a posi-
tive result in the LMX test was subjected to a second stage of test-
ing by Luminex Single Antigen (LSA) beads (LIFECODES LSA Class
I and/or LSA Class II Single Antigens, Immucor Transplant
Diagnostics). Analysis was performed using a fluorocytometer
(LABScan 200 Flow Analyser, Luminex, Austin, TX, USA). The
results were analysed using MatchIt software (Immucor
Transplant Diagnostics). Currently, no standard median fluores-
cence intensity (MFI) cut-off values exist, therefore the raw values
of patient’s serum >1000 were considered positive, as has been
previously indicated in the literature.
Continuous data were expressed as the arithmetic mean or
median and categorical data as n (%). To determine statistically
significant differences between the two techniques used in HLA
antibody detection, data were compared with the use of the chi
quadrat test and the Mann–Whitney U test. A two-sided P-value
<0.05 was considered statistically significant. Statistical analy-
sis was performed using MedCalc version 12.13. (MedCalc
Software, Ostend, Belgium).
Results
Of the 163 patients included in the analysis, 65 (39.88%) patients
were female and 98 (60.12%) were male. The average age was
55.85611.86 years.
One-third of the patients [49 (30%)] on the WL were not
exposed to any SEs. Two-thirds of patients [114 (70%)] were
exposed to one of the SEs (63 subjects) or to combinations of
two (43 subjects) or three SEs (8 subjects) (Figure 1).
HLA antibody screening techniques | 853
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/10/6/852/4036278 by M
edicinski Fakultet R
ijeka user on 04 D
ecem
ber 2018
The number of sensitized patients grew proportionately
with the number of sensitizing factors. HLA antibodies were
detected (by Luminex assay) in 10 (20.41%) patients who did not
have any SEs, in 19 (30.16%) patients after one SE, and in 22
(51.16%) patients after two SEs. Exposure to three SEs caused
HLA antibody generation in all patients. The relationship
between HLA sensitization and the number of SEs is shown in
Figure 2.
Regardless of the combination, the most frequent SEs were
blood transfusions, in 92 (56.44%) patients, while previous preg-
nancies were reported in 57 (34.97%) patients and previous
transplants were performed in 24 (14.72%) patients.
Considering the type of SE, 42 (25.77%) patients received a
transfusion only, 20 (12.27%) women reported a history of pre-
vious pregnancies only and 1 (0.61%) patient had a previous
transplant. In terms of combinations of SEs, 28 (17.18%) women
had a history of both transfusions and pregnancies, 14 (8.59%)
recipients had previous transfusions and transplants, only 1
(0.61%) patient had both a previous transfusion and pregnancy,
while all three SEs were reported in 8 (4.91%) patients.
Figure 3 shows the proportion of the patients with detected
HLA antibodies in pre-transplant sera according to the type of
SE. Previous transplantation represents the strongest immuno-
genic stimulus regardless of the combinations with other SEs,
while pregnancy as an isolated event was the weakest sensitiz-
ing factor.
HLA antibodies were not detected by either the CDC or Luminex
techniques in the pre-transplant sera of 104 (63.80%) patients,
while the sera of 59 (36.20%) patients were found to be positive for
IgG HLA antibodies by the CDC and/or Luminex method.
In terms of the technique, HLA antibodies were detected in
23 (14.11%) patients by CDC and Luminex (CDCþLUMþ) and in
an additional 36 (22.09%) by Luminex only (CDCLUMþ). The
difference between the proportion of patients with HLA anti-
bodies detected by CDC and/or Luminex was not statistically
significant (v2 ¼ 0.18, P ¼ 0.673).
Table 1 shows HLA sensitization detected by different tech-
niques according to exposure to the SEs in patients on the kid-
ney transplant WL. Considering different SEs, all patients with a
history of previous transplantation only, or in combination with
another SE, were sensitized.
SEs induced the HLA sensitization in 49 patients; however,
HLA antibodies were also detected in 10 patients without a his-
tory of SEs. These antibodies were detected by Luminex only.
Figure 4A–C shows the prevalence of sensitized patients accord-
ing to exposure to SEs and the class I and/or class II HLA antibod-
ies detected by the two different techniques. Antibodies against
mixed HLA antigens class I/II were mostly detected by the CDC
and Luminex in parallel. Luminex was more sensitive in the
detection of HLA class I, and especially of class II, compared with
the CDC assay. Thus the CDC technique finds it difficult to distin-
guish class II antibodies using a panel of T and B lymphocytes.
The strength of the HLA antibody expressed as MFI was sig-
nificantly higher in patients with antibodies detected by both
techniques (CDCþLUMþ) compared with the group of patients
with antibodies detected by Luminex only (CDCLUMþ) for HLA
class I antibodies (MFI 4789 versus 3086; P< 0.001) and class II
Fig. 2. Distribution of patients with and without detected HLA antibodies accord-
ing to the number of SEs.
Fig. 3. Proportion of patients with and without HLA antibodies according to exposure to SEs. TX, transplantation; TF, blood transfusion; P, pregnancy.
30%
39%
26%
5%
Number of 
sensizing events
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Fig. 1. Distribution of patients on the kidney WL exposed to SEs (previous trans-
plantation, pregnancy and/or blood transfusion).
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antibodies (MFI 5715 versus 4606; P< 0.001). The results are
shown in Figure 5A and B.
Ten patients who were not exposed to any senstizing event
were HLA antibodies positive using Luminex technique and
negative using CDC technique. Using Luminex technique Class I
and Class II antibodies were detected. Among Class I antibodies
32 specificities were detected, and among Class II 21 specific-
ities. Median values of peak MFI of HLA antibodies class I were
significantly higher from median values of peak MFI of Class II
specificities. (MFI 3324 versus 1779; P¼ 0.010) (Figure 6).
Discussion
Previous transplants, blood transfusions and pregnancies are
major SEs that can cause HLA alloimmunization [13]. Two-
thirds of the patients (69.94%) on the WL at our centre were
exposed to one or more sensitizing factor, which is consistent
with the literature [14, 15].
The risk of developing HLA antibodies is proportional to the
number of sensitizing factors. The combination of SEs represents
a stronger stimulus for HLA antibody generation than exposure
to a single SE. In our study, most patients (38.65%) with a history
of immunization had only one SE and HLA antibodies occurred in
one-third (30.16%) of them, based on Luminex results. Fewer
patients (26.38%) had been exposed to combinations of two SEs,
and more than a half (51.16%) of these became sensitized. After
exposure to three SEs (4.91%), HLA antibodies were detected in all
patients (100%). Concerning the techniques used in antibody
detection, the difference in sensitivity between CDC and Luminex
are interesting; the sensitivity mirrors the number of SEs. The
higher sensitivity of Luminex is pronounced after exposure to a
single SE (more patients had antibodies detected by Luminex only,
while the CDC technique gave negative results). The difference
between Luminex and CDC results disappears after two SEs, while
exposure to three SEs caused sensitization detected by both tech-
niques in almost all patients. The increased number of SEs causes
antibody generation in higher concentrations that can be detected
by less sensitive methods. The cumulative immunizing effect of
different SEs has been recognized by several studies [13, 16].
The most frequent SE was blood transfusion. More than half
(56.44%) of the patients received one or more red blood concen-
trates (RBCs), which is less than in previously published studies
[14]. Most studies do not specify whether patients received trans-
fusions after being placed on the WL or during the pre-transplant
period. In this study, almost all transfused patients received RBCs
(with or without leucocyte reduction) before registration on the
WL. While being on the WL, only 11 (6.75%) patients were trans-
fused. The US Renal Data System reports that 30% of transplant
candidates on WLs received at least one blood transfusion, while
Yabu et al. [13] reported only 8.87% [13, 17]. Other SEs were less
frequent; about one-third of transplant candidates had a history
of pregnancy (34.97%) and the SE with least prevalence was pre-
vious transplants (14.72%).
Evaluation of the impact of SEs on HLA sensitization varies
according to the techniques used. Transfusions caused HLA anti-
body generation in only 9.52% of transplant candidates when the
serum screening was performed by CDC, but when tested by
Luminex, the rate of sensitized patients increased to 25.77%. In
our study the positivity rate detected by CDC is lower than in
published data. Opelz et al. [18] reported that 28% of transfused
patients developed HLA antibodies in the CDC assay. However,
Luminex results in our study are in accordance with other
reports. Hyun et al. [19] reported a 33% positive rate in transfused
patients, while Leffell et al. [20] reported 20%. The reports on the
positivity rate detected by CDC are mostly old, and lower results
in our study can be explained by the differences in lymphocyte
panels among centres and the various approaches to anaemia
treatment by transfusions of different types of blood units.
HLA sensitization was detected in 10% (CDC) versus 12.27%
(Luminex) of women with a history of pregnancies. The
reported incidence is 18–30% tested by the CDC method and
>50% when tested by Luminex [21–23]. The age of women in the
tested groups may be the cause of the different results, as the
titre of HLA antibodies declines over time [24]. In our study, only
one patient had previous transplant as the sole SE.
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Fig. 4. Total number of patients with HLA antibodies (A) class I, (B) class II and (C) class I/II detected by CDC and/or Luminex. TX, transplantation; TF, blood transfusion;
P, pregnancy.
Table 1. Total number and proportion of patients exposed to differ-
ent SEs according to the HLA antibody screening results by the CDC
and Luminex techniques
Type of SE
HLA antibodies screening results
Neg, n (%) CDCLUMþ,n (%) CDCþLUMþ,n (%)
No SE (n ¼ 49) 39 (79.59) 10 (20.41) 0
TX (n ¼ 1) 0 1 (100.00) 0
TF (n ¼ 42) 31 (73.81) 7 (16.67) 4 (9.52)
P (n ¼ 20) 13 (65.00) 5 (25.00) 2 (10.00)
TX þ TF (n ¼ 14) 0 6 (42.86) 8 (57.14)
TX þ P (n ¼ 1) 0 0 1 (100.00)
TF þ P (n ¼ 28) 21 (75.00) 5 (17.86) 2 (7.14)
TX þ TF þ P (n ¼ 8) 0 2 (25.00) 6 (75.00)
Total (n ¼ 163) 104 (63.80) 36 (22.09) 23 (14.11)
Neg, negative; TX, transplantation; TF, blood transfusion; P, pregnancy.
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Considering the difference between HLA class I and II anti-
bodies detected by the two techniques, the higher sensitivity of
Luminex is evident when a single class is present in the tested
serum, especially class II antibodies. In our laboratory, the CDC
technique is performed using a panel of unseparated (T and B)
lymphocytes. HLA class I antigens are expressed on T lympho-
cytes and class II antigens on B lymphocytes. In the whole lym-
phocyte population used in the CDC assay, the proportion of B
lymphocytes is low, therefore the titre of HLA class II antibodies
is below the sensitivity threshold of the CDC test. In patients
with the presence of both class I and II antibodies, Luminex sen-
sitivity is not so dominant when compared with the CDC
technique. A likely explanation may be that most patients posi-
tive for both antibody classes had a history of previous kidney
transplantation, confirming that solid organ transplantation
represents the strongest immunizing event [19].
In our study, 10 male patients without reported SEs had anti-
bodies that were detected by Luminex only. More specificities
were found for class I antibodies. The MFI was low for both
classes, but class I antibodies showed significantly higher MFIs
compared with class II antibodies. The presence of HLA antibod-
ies in non-immunized patients may be explained by the response
to cross-reactive epitopes found in microorganisms, ingested
proteins and allergens (natural alloantibodies), or as reactivity
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Fig. 5. Comparison of MFI values between HLA antibodies (A) class I and (B) class II detected by CDC and Luminex (CDCþLUMþ) and antibodies detected by Luminex
only (CDCLUMþ) in sensitized patients on the kidney transplant WL exposed to SEs. The box-and-whisker plot shows median values of peak MFI for every specificity
of HLA antibody that is considered positive (MFI1000) in each patient.
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directed against denatured molecules (neo-epitopes) and
exposed cryptic epitopes resulting from possible conformational
changes of the HLA protein that may occur during the manufac-
turing process [25–28].
Implementation of more sensitive techniques in HLA anti-
body detection has enabled new insights into their occurrence,
activity and clinical relevance in organ transplantation. The
association between DSAs detected by CDC with hyperacute or
acute graft rejection has been known for decades [10]. Reports
on the clinical importance of DSAs detected in Luminex-based
assays only are conflicting. Several studies have shown that the
presence of DSAs detected exclusively by Luminex has no clini-
cal relevance to graft survival [29, 30]. Others, however, reported
an association between DSAs and significantly increased graft
loss even with a negative CDC and/or FC crossmatch [3, 31, 32].
The threshold of clinically relevant MFI values is also a matter
of debate. Low levels of HLA DSAs detected by a Luminex assay
before transplantation (MFI<1000 or<2000) are unlikely to have
a deleterious effect on the graft [33, 34]. Several authors have
demonstrated significantly lower graft survival in patients with
higher MFIs [3, 35]. To assess the clinical impact of complement
binding antibody on graft survival, several modifications of
Luminex-based assays have been made. However, while some
studies have shown that complement-fixing DSAs are more rel-
evant in graft survival than non-complement-fixing DSAs [13,
36, 37], some authors were unable to demonstrate such an asso-
ciation [38, 39]. Further investigations and methodology advan-
ces are needed to bring us closer to these answers.
Conclusion
Exposure of patients on WLs to blood transfusions, pregnancies
or previous transplants represents a risk factor of developing
HLA antibodies that are considered a major immunologic bar-
rier to successful transplantation. Blood transfusions are the
most frequent and the most susceptible to our influence com-
pared with other SEs. They should be minimized or avoided in
transplant candidates whenever possible. HLA antibody testing
is critical in transplantation risk assessment, and CDC is widely
used as a conventional cell-based method. It has low sensitivity
and low resolution in determining antibody specificity, but high
positive predictive value for antibody-mediated graft rejection.
Luminex is a semi-quantitative SPA that is more sensitive than
CDC, enabling better characterization of antibodies, but due to
increased sensitivity, it may reveal the presence of antibodies
with dubious clinical relevance. Based on the characteristics of
both methods, the results have to be evaluated in combination
with the clinical background and history of the patient’s expo-
sure to SEs in order to determine unacceptable HLA antigen
mismatches in the pre-transplant period.
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